{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:49:10Z","timestamp":1790372950426,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ijantimicag.2023.106811","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T01:56:31Z","timestamp":1680918991000},"page":"106811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of a real-time diagnostic and antimicrobial stewardship workflow on time to appropriate therapy for infections caused by multidrug-resistant Gram-negative organisms"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8549-7578","authenticated-orcid":false,"given":"Katie A.","family":"McCrink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailynn J.","family":"DeRonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8542-4870","authenticated-orcid":false,"given":"Adriana","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Rosello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-125X","authenticated-orcid":false,"given":"Yoichiro","family":"Natori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio V.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Perez-Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian M","family":"Abbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana D.","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106811_bib0001","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Atlanta: CDC, 2019. Available at: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf [accessed 25 November 2020]."},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0002","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","article-title":"Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?","volume":"17","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0003","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270003257225","article-title":"Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem","volume":"43","author":"Kuti","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0004","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/AAC.02399-12","article-title":"Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae","volume":"57","author":"Giamarellou","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0005","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/jac\/dkq285","article-title":"The impact of polymyxin B dosage on in hospital mortality of patients treated with this antibiotic","volume":"65","author":"Elias","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0006","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/cid\/cis909","article-title":"Association between colistin dose and microbiologic outcome in patients with multidrug-resistant Gram-negative bacteremia","volume":"56","author":"Viscari","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0007","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1177\/0897190014546836","article-title":"Aminoglycoside-induced nephrotoxicity","volume":"27","author":"Wargo","year":"2014","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0008","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1517\/14656566.2013.763030","article-title":"Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum beta-lactamases and carbapenemases)","volume":"14","author":"Lynch","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0009","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0010","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0011","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0012","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1128\/AAC.00338-07","article-title":"Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0013","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0014","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3524-8","article-title":"A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long?","volume":"18","author":"Lodise","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0016","doi-asserted-by":"crossref","first-page":"ofz194","DOI":"10.1093\/ofid\/ofz194","article-title":"Antimicrobial resistance or delayed appropriate, therapy \u2013 Does one influence outcomes more than the other among patients with serious infections due to carbapenem-resistant versus carbapenem-susceptible Enterobacteriaceae?","volume":"6","author":"Lodise","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115069","article-title":"Implementing carbapenem-resistance testing algorithms for Enterobacterales and Pseudomonas aeruginosa: diagnostic and antimicrobial stewardship with timely infection prevention","volume":"97","author":"Vega","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ckj\/sfs160","article-title":"The RIFLE and AKIN Classifications for acute kidney injury: a critical and comprehensive review","volume":"6","author":"Lopes","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0019","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. IDSA 2020."},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0020","doi-asserted-by":"crossref","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-World Experience with Ceftazidime-Avibactam for Multi-Drug Resistant Gram-Negative Bacterial Infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0021","doi-asserted-by":"crossref","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumonia Bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106811_bib0022","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:25Z","timestamp":1760377525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0924857923000900"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106811","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of a real-time diagnostic and antimicrobial stewardship workflow on time to appropriate therapy for infections caused by multidrug-resistant Gram-negative organisms","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106811"}}